Akebia secures up to $140 million term loan from Symbiotic Capital, repays BlackRock-linked debt
Akebia drew an initial $60 million tranche on November 12, 2026 to fully retire its $55 million Kreos/BlackRock facility, with up to $80 million more available at the lender's discretion.
Akebia Therapeutics, Inc. announced on November 16, 2026 that it had entered into a senior secured term loan facility with Symbiotic Capital. The Symbiotic Loan Facility consists of an initial tranche of $60.0 million that was fully funded at closing and the ability to request up to an additional $80.0 million, which Symbiotic Capital may fund at its discretion.1 The facility closed on November 12, 2026.1
Akebia used the proceeds from the initial tranche to repay in full its $55.0 million loan facility with BlackRock.1 That prior facility had been with Kreos Capital VII (UK) Limited, which are funds and accounts managed by BlackRock Inc.1 The company paid off the $55.0 million Kreos loan in full, including customary termination fees and other related expenses.1 Net proceeds from the initial $60 million tranche were approximately $58.6 million after deducting debt issuance costs, fees and expenses.1
The new facility carries a five-year term. The Term Loan Facility has a maturity date of November 12, 2031.1 It will accrue interest at a variable annual rate equal to the greater of 11.5% or the Wall Street Journal prime rate plus 4.5%, subject to a cap of 15.0% per annum.1 There is no scheduled amortization, with all principal and accrued interest due in full at maturity.1
As part of the deal, Akebia issued warrants to purchase a total of 3,441,352 shares of common stock at an exercise price of $0.6974 per share, with additional warrant coverage tied to any future discretionary tranche draws.1 The warrants are exercisable at any time prior to November 12, 2033.1
Akebia reaffirmed its cash runway guidance of at least two years, according to Chief Financial and Chief Business Officer Erik Ostrowski.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.